Business
Theravance Biopharma to Participate in Upcoming Investor Conferences
DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"\n DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:\n \n \n \n \n \n \n \n \n 8th Annual Evercore Healthcare ConferenceLocation: Coral Gables, FLFormat: Fireside ChatDate: Thursday, December 4, 2025Time: 8:20-8:40 AM ETWebcast\n \n Oppenheimer Movers in Rare Disease SummitLocation: New York, NYFormat: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025Time: 2:15-2:45 PM ET\n Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.\n A live webcast of the Evercore presentation may also be accessed on the \"Events and Presentation\" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.\n \n About Theravance BiopharmaTheravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.\n For more information, please visit www.theravance.com.THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).\n YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.\n Contact:[email protected]\n \n View original content to download multimedia:https://www.prn...